Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant ARID1A: igniting cancer immunotherapy.

Trends in immunology - 1 Aug 2024

Vokshi Bujamin H, Toska Eneda

Abstract excerpt

Maxwell et al. show that ARID1A loss enhances antitumor immunity by triggering a type I IFN response through the cGAS-STING pathway, thereby promoting T cell infiltration and cytotoxicity. These findings highlight SWI/SNF inhibitors as a strategy to augment immunotherapy efficacy by potentially transforming non-responsive tumors into responders and advancing approaches to cancer treatment.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA-Binding Proteins
Share to Immunotherapy
Share to Membrane Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Signal Transduction

Share to Transcription Factors

Source

Identifiers

PMID: 39068111
DOI: 10.1016/j.it.2024.07.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant ARID1A: igniting cancer immunotherapy.PMID 39068111Read ↗

Loss of ARID1A 'loops' in STING.Semantic proximity Read ↗

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.Semantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS- STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsSemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors.Semantic proximity Read ↗

Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy.Semantic proximity Read ↗

CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancerSemantic proximity Read ↗

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.Semantic proximity Read ↗

Entanglement of Methylation Changes and cGAS-STING Signaling in Non-Small-Cell Lung CancerSemantic proximity Read ↗

<i>SMARCA4</i> mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.